Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898407 | 0.83 | CTSK (0.45) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL8245338 | 0.82 | TSHR (0.54) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL376117 | 0.82 | CACNA1B (0.48) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL8245341 | 0.82 | TSHR (0.54) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL192185 | 0.82 | CACNA1B (0.48) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL4233928 | 0.82 | CACNA1B (0.48) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL2714461 | 0.81 | CTSK (0.49) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL6842296 | 0.81 | CACNA1B (0.48) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL30089915 | 0.81 | CACNA1B (0.48) | ITGB3ITGA2BCTSKCTSSHDAC4 | |
| SCHEMBL19941820 | 0.80 | BTK (0.46) | ITGB3ITGA2BCTSKCTSSHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008053157-A1 | AMINOHETEROARYL COMPOUNDS AS FOR THE TREATMENT OF DISEASES MEDIATED BY C-MET KINASE ACTIVITY | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |